Benchmark Maintains Speculative Buy on Unicycive Therapeutics, Lowers Price Target to $13

Benchmark analyst Bruce Jackson maintains Unicycive Therapeutics (NASDAQ: UNCY ) with a Speculative Buy and lowers the price target from $18 to $13.